
GlaxoSmithKline receives approval for Advair Diskus 250/50
GSK's fluticasone/salmeterol combination powder is apporved by FDA for reduction in COPD exacerbations.
Advair Diskus 250/50, from GlaxoSmithKline, may now be used for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD) who have a history of exacerbations. The combination drug, which contains fluticasone propionate 250 mcg and salmeterol 50 mcg, was proven effective for this new indication in two one-year clinical trials involving a total of 1,579 patients. Patients treated with Advair had a 30% reduction in the rate of annual exacerbations compared with salmeterol (p<0.001) and a significantly lower annual rate of exacerbations requiring treatment with oral corticosteroids (p<0.001). According to GSK, the
To go to the Drug Topics homepage,
To see more Daily News articles,
To go to the Drug Topics homepage,
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.




















































































































































